Innate Pharma S.A. (IPHA) PT Lowered to $12 at Citi
Tweet
Share
E-mailGet Alerts IPHA Hot Sheet
Price: $2.11 -2.76%
Rating Summary:
5 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 18 | New: 28
Rating Summary:
5 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 18 | New: 28
Join SI Premium – FREE
Citi analyst Yigal Nochomovitz lowered the price target on Innate Pharma S.A. (NASDAQ: IPHA) to $12.00 (from $16.00) while maintaining a Buy rating.
You May Also Be Interested In
- JPMorgan Downgrades Inpex Corp (1605:JP) to Neutral
- Obayashi Corporation (1802:JP) PT Lowered to JPY3,300 at Nomura/Instinet
- VersaBank (VBNK) PT Lowered to $20 at Raymond James
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
